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Abstract 
Purpose Oral agents for cancer treatment are increasingly prescribed due to their benefits. However, oral cancer 
medications are difficult to handle and have a considerable potential for side effects. This type of therapy requires 
a high level of self-management competence by the patient. A standardized patient education program provided 
by physicians and oncology nurses may positively influence the handling of oral agents. The aim of the study was 
to evaluate the impact of a standardized patient education program provided by specially trained oncology nurses 
on therapy management regarding side effects and unplanned therapy interruptions.  
Methods One hundred sixty-five patients from 28 office-based oncology practices from all over Germany 
participated in this cluster-randomized controlled study. Patients of both intervention (n = 111) and standard care 
groups (n = 54) received the usual oncologist counseling; in addition, the patients from the intervention group (k = 
17 practices) received an education from specially trained oncology nurses. The time of observation was 3 
months per patient. 
Results The patients of the intervention group reported fewer side effects (skin rash, pain, fatigue, nausea, 
vomiting). Patients in the standard care group interrupted the therapy more frequently without informing their 
oncologist, compared to the intervention group. 
Conclusions Patients benefit from a standardized patient education program provided by specially trained 
oncology nurses. They tend to handle side effects and critical situations better. 
Keywords Oral cancer therapy • Patient education • Oncology nurses • Therapy-related side effects • Unplanned 
therapy interruption 
Introduction 
Outpatient oncology care is undergoing a profound change. New oral cancer drugs are continuously approved 
and complement or replace intravenous chemotherapy. From 2011 to 2014, 25 new oral agents were approved 
by the US Food and Drug Administration (FDA) [1]. About 25% of all hematology-oncology drugs in development 
are designed for oral administration [1–3]. Based on estimations by the Scientific Institute of Office-Based 
Hematologists and Oncologists (WINHO), more than 40% of the patients undergoing cancer therapy in ambulant 
care in Germany receive oral agents [4]. These drugs revealed a great potential in cancer care. For example, the 
approval of imatinib (Glivec®) in 2001 for the therapy of chronic myeloid leukemia induced a 30% decrease in 
mortality [5]. On the one hand, this advancement of therapy is an important step in cancer treatment. On 
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the other hand, it poses a challenge for oncology care [6]. In the case of intravenous chemotherapy, the drug is 
administered under the supervision of the oncology team. When it comes to oral agents, however, the place of 
treatment is the patient’s home. In this treatment setting, correct treatment management cannot be guaranteed 
without first identifying the patients’ needs in order for the patients to be empowered and become an expert in 
their own treatment because cancer therapies are commonly difficult to handle and the medication often shows a 
high risk of side effects and interactions with other drugs [3, 7, 8]. Care providers are challenged by the question 
of how patients, who are mostly elderly and multimorbid, and their supporting relatives can be equipped with 
essential competencies to manage their treatment independently. Before patients start their cancer therapy, they 
are usually provided with information about the treatment by their physician [9]. However, patients often feel 
overwhelmed by all the details in this stressful situation and tend to have a reduced capacity to assimilate 
complex information [10]. Education and additional support at the beginning and in the course of the treatment 
can be a useful approach for patients to better handle this situation [1, 10–14]. 
Recent studies showed the positive impact supportive care programs provided by nurses can have on patients 
[3, 11, 15–17]. Patient-focused motivation techniques and education performed by nurses are suitable to 
strengthen the patients’ understanding of risks and benefits of the anti-cancer treatment and oral agents [3]. 
These care programs can prevent an incorrect medication intake due to misunderstandings [18], lead to a 
decrease in treatment-related symptoms like pain and fatigue, and reduce critical events [3, 11]. In addition, 
patient education can facilitate supportive care through a better communication between patient and healthcare 
provider, and it may advance the early detection of adverse toxicity events and foster rapid symptom 
management [15]. 
Goal 
The aim of our study was to evaluate the effectiveness of a standardized patient education program provided by 
specially trained oncology nurses on therapy management regarding side effects and unplanned therapy 
interruptions in outpatient oncology care. 
Patients and methods 
A prospective cluster-randomized trial was conducted. The study was approved by the ethics committee of the 
Bavarian medical chamber. The study was the main part of the project Patients’ Competence in Oral Cancer 
Therapy (PACOCT), which was funded by the German Federal Ministry of Health within the National Cancer Plan. 
Beside the intervention study, a patient education program provided by oncology nurses, we surveyed the current 
situation of patients undergoing oral anti-cancer therapy and the current situation of patient education and cancer 
therapy with oral agents in outpatient oncology practices. Furthermore, we aimed to identify structural and 
organizational needs for a standardized patient education program. 
Setting and sample 
All oncology practices from the WINHO network (k = 196 practices) were invited to participate in the study. The 
WINHO Network is a unique union of outpatient oncology practices from all over Germany for scientific 
collaboration. The practices which agreed to participate in the study (k = 28) were randomized on practice level 
(2:1) into an intervention and a standard care group. Accordingly, cluster-wise randomized patients were assigned 
to the groups depending on the practice’s assignment. Patients were recruited during an 8-month period, from 
March until October 2014, and gave their informed consent prior to study participation. Patients were observed at 
baseline (T0) and through four follow-up periods (T1–T4) over a span of 3 months between March and December 
2014. The recruitment flow is shown in Fig. 1. 
Patients were included if they were aged 18 years or older, newly adjusted on an oral anti-cancer therapy (i.e., 
no prior oral anti-cancer therapy; prior intravenous cancer therapies were permitted), not receiving concurrent 
intravenous anti-cancer therapy, and receiving oral agents which were approved by the German or the European 
drug authorities (BfArM/EMA). Patients with an anti-hormone therapy were only included if they had metastatic 
breast cancer or metastatic prostate cancer. Patients with a long-term solely adjuvant anti-hormone therapy were 
excluded. Patients who fit the criteria were approached and informed about the subject of the study by their 
physicians before the start of therapy. 
Sample size 
A sample size calculation was done which assumed that for a two-tailed group comparison at the p < 0.05 
significance level and a minimum effect size of 0.3, 176 patients per group would be necessary to achieve a 
power of 80%. In virtue of the intracluster design, we also calculated the design effect using 0.01 as an estimate 
of intracluster correlation. This value was used as median in an analysis of 31 cluster-based studies in primary 
care [19] and seems suitable as an approximation for oncology practices. The design effect was calculated with 




Fig. 1 Study recruitment flow 
minimum of 210 patients were required. Therefore, each practice was asked to recruit 20 patients. 
Standard care 
In the standard care group, patients were routinely informed about the treatment, the drug, and the adverse 
effects by the physician. For the duration of the study, patients scheduled regular treatment appointments as they 
would have outside a study. Study nurses in the standard care group received an online briefing about the use of 
the measuring instruments. For side effect documentation, a self-developed diary was used. The 





The patients in the intervention group took part in a patient education program provided by oncology nurses. This 
program was developed on the basis of the MOATT—the Oral Agent Teaching Tool from the Multinational 
Association of Supportive Care in Cancer (MASCC). This care program conversation guide addresses 
medication-specific topics like the shape and look of the pills, intake routine, storage, drug interactions, side effect 
prevention, and other daily clues for the patient [20]. Furthermore, a standardized form covering these topics was 
to be filled out jointly by patients and nurses. Prior to the study, oncology nurses of the intervention group were 
trained in relevant subjects like motivational conversation techniques, action mechanisms of the drugs, research 
strategies, and usage of the study instruments. The patient- and medication-specific guidance provided by the 
nurses was to address the patients’ needs and social resources and go beyond standard patient information. After 
the patient received general information and training from the physician with regards to treatment when starting 
therapy, patient and nurse arranged an appointment for the first education session within 1 week. In preparation 
for the first session, the patient was asked to fill out a self-assessment sheet concerning health literacy, expected 
adherence, social background, care dependency, depression, and geriatric situation. Based on all available 
information including the patient’s chart and the medication plan, the nurses structured the first patient- and 
medication-specific education session. The first patient education session (T0) was not to take more than 45 min. 
At first, the patient information previously provided by the physician was repeated. On this basis, nurses had to 
conduct the education session and communicate the medication-specific contents for each patient. This patient 
education was repeated during all follow-up appointments. The first two appointments (T1 and T2) were 
scheduled at an interval of 2 weeks, the further appointments (T3, T4) with a gap of 4 weeks. The duration of 
these follow-up appointments was not to exceed 30 min. The measurement instruments were the same for the 
intervention group as for the standard care group. 
Outcome measures 
As outcomes, frequencies of therapy-related side effects (i.e., skin rash, pain, nausea, vomiting, fatigue, and 
diarrhea) were surveyed on a daily basis during the intervention cycle through a diary. Furthermore, we surveyed 
the frequency of unplanned therapy interruptions (UTI). In order to obtain more details about UTI, we asked 
whether they were initiated by the physician or by the patient. Therapy interruptions were monitored at each time 
of measurement during the intervention. To collect these data, the study nurses had to keep all outcomes on 
record. On the patient side, we used a diary for side effects. 
Data analysis 
The analysis of side effects is based on the diaries that were kept by the patients from both groups. For each time 
of measurement, we counted the number of reported side effects in the preceding period. The number of side 
effects at T1 reflects the frequency of side effects between T0 and T1. Consequently, the number of side effects 
is a count variable, which can be analyzed using a Poisson regression. However, one assumption of this model is 
that the mean of the outcome variable equals the variance [21]. Here, for all side effects, the variance of the 
respective count variable is much larger than the mean, which is known as overdispersion. To overcome this 
issue, we used the more appropriate negative binomial regression model [21]. Another issue concerns the 
repeated measurements (T1–T4), which violate the independence assumption that most statistical models rely on 
and usually result in standard errors that are too small. We estimated clustered standard errors to correct for this 
issue. The statistical analyses were performed using R 3.3.1 [22] and Stata 14.1. 
To test for differences in side effects between the control and the intervention group, negative binomial 
regression models were estimated. Based on these estimations, the predicted counts for each group as well as 
the predicted differences between the groups’ counts for each of the four times of measurement (T1–T4) were 
computed. The results are shown in Fig. 2. Additional models were estimated that include time, i.e., the time of 
measurement, as a linear and a squared term to test for nonlinear effects (u-shaped or inverted u-shaped effects). 
In these polynomial regressions, the grouping (control vs. intervention) variable was included as an interaction 
term to test for differences in the progression of the side effects. 
In terms of UTI, three possible outcomes can be distinguished. First, no UTI occurred. Second, the oncologist 
advised the patient to interrupt the therapy. Third, the patient decided to interrupt the therapy by him-/herself. To 
estimate the chances for the three outcomes for each time of measurement, we calculated odds ratios for the 
intervention and for the standard care group. 
Results 
In total, we recruited 165 patients from 28 oncology practices from all over Germany. For the intervention group, 
111 patients were recruited and 54 patients for the standard care group (Fig. 1). The mean age in the intervention 
group was 69.32 years (SD = 12.31) and 71.35 years in the standard care group (SD = 10.9). While gender was 




Fig. 2 Predicted number of events. Note: values at the bottom of the plots denote p values for group differences 
between standard care and intervention group 
the standard care group (50.0% n = 27, 50.0% n = 27), women (55.9%, n = 62) were overrepresented in the 
intervention group (men 44.1%, n = 49). In both groups, most of the patients lived in a relationship (intervention 
70.1%, standard care 77.4%). The most frequent diagnoses were colon cancer (intervention 12.9%, standard 
care 20.8%), myeloproliferative neoplasms (intervention 14.9%, standard care 8.3%), breast cancer (intervention 
11.9%, standard care 6.2%), and lung cancer (intervention 6.9%, standard care 10.4%). The most frequently 
prescribed agents were capecitabine (intervention 25.2%, standard care 30.2%), hydroxyurea (intervention 
20.7%, standard care 7.5%), temozolomide (intervention 9.9%, standard care 3.8%), lenalidomide (intervention 
4.5%, standard care 9.4%), and erlotinib (intervention 4.5%, standard care 9.4%) (Table 1). 
Side effects 
Figure 2 illustrates the predicted numbers of each side effect. The y-axis shows the predicted number of side 
effects for standard care and the intervention group across the four follow-up points. In almost all instances, the 
intervention group tended to experience fewer side effects for fatigue, nausea, pain, skin rash, and vomiting 
(exception: diarrhea) than the standard care group. Especially the curves for fatigue and skin rash underline these 
findings. However, despite the observable trend to fewer side effects, there was only one statistically significant 
difference between the groups. The intervention group reported at T3 (8 weeks after treatment start) significantly 
fewer skin rash (p = 0.02) than the standard care group. In reference to the trends toward fewer side effects, 
almost all plots of the  
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Table 1 Sociodemographic and clinical characteristics of the sample 
 Standard care Intervention 
 % n % n 
Women 50.0 27 55.9 62 
Men 50.0 27 44.1 49 
Age (mean) 71.35 (SD = 10.9)  69.32 (SD = 12.31)  
Single 20.8 11 28.3 30 
In a relationship 77.3 41 70.7 75 
Care home 1.9 1 1.0 1 
Entity (ICD10)     
C16—Malignant neoplasm of stomach 0.0 0 2.0 2 
C17—Malignant neoplasm of small intestine 0.0 0 1.0 1 
C18—Malignant neoplasm of colon 20.8 10 12.9 13 
C20—Malignant neoplasm of rectum 2.1 1 8.9 9 
C22—Malignant neoplasm of liver and 
intrahepatic bile ducts 
4.2 2 3.0 3 
C25—Malignant neoplasm of pancreas 2.1 1 0.0 0 
C34—Malignant neoplasm of bronchus and 
lung 
10.4 5 6.9 7 
C41—Malignant neoplasm of bone and articular 
cartilage of other and unspecified sites 
0.0 0 1.0 1 
C43—Malignant melanoma of skin 4.2 2 0.0 0 
C50—Malignant neoplasm of breast 6.2 3 11.9 12 
C56—Malignant neoplasm of ovary 2.1 1 1.0 1 
C61—Malignant neoplasm of prostate 8.3 4 2.0 2 
C64—Malignant neoplasm of kidney, except 
renal pelvis 
4.2 2 4.0 4 
C71—Malignant neoplasm of brain 4.2 2 9.9 10 
C76—Malignant neoplasm of other and ill-
defined sites 
0.0 0 1.0 1 
C90—Multiple myeloma and malignant plasma 
cell neoplasms 
8.3 4 5.9 6 
C91—Lymphoid leukemia 4.2 2 0.0 0 
C92—Myeloid leukemia 6.2 3 6.9 7 
C93—Monocytic leukemia 0.0 0 1.0 1 
C94—Other leukemias of specified cell type 0.0 0 1.0 1 
D45—Polycythaemia vera 0.0 0 4.0 4 
D46—Myelodysplastic syndromes 2.1 1 0.0 0 
D47—Other neoplasms of uncertain or 
unknown behavior of lymphoid, hematopoietic, 
and related tissue—myeloproliferative 
neoplasms 
8.3 4 14.9 15 
D75—Other diseases of blood and blood-
forming organs 
0.0 0 1.0 1 
K63—Other diseases of intestine 2.1 1 0.0 0 
Agent     
Capecitabine 30.2 16 25.2 28 
Hydroxyurea 7.5 4 20.7 23 
Temozolomide 3.8 2 9.9 11 
Lenalidomide 9.4 5 4.5 5 
Erlotinib 9.4 5 4.5 5 
Imatinib 3.8 2 3.6 4 
Pazopanib 5.7 3 1.8 2 
Everolimus 0.0 0 4.5 5 
Sorafenib 3.8 2 2.7 3 
Abiraterone 7.5 4 0.9 1 




Table 1 (continued) 
 Standard care Intervention 
 % n % n 
Sunitinib 1.9 1 2.7 3 
Vemurafenib 5.7 3 0.0 0 
Treosulfan 1.9 1 0.9 1 
Exemestane 1.9 1 0.9 1 
Nilotinib 0.0 0 1.8 2 
Afatinib 0.0 0 1.8 2 
Dasatinib 0.0 0 1.8 2 
Chlorambucil 3.8 2 0.0 0 
Pomalidomide 0.0 0 1.8 2 
Gefitinib 0.0 0 0.9 1 
Lapatinib 0.0 0 0.9 1 
Enzalutamide 0.0 0 0.9 1 
Etoposide 0.0 0 0.9 1 
Note: For these analyses, the statement “no response” was not considered 
intervention group follow an inverted u-shaped curve over time. For fatigue and pain, we found trends for slower 
increase in side effects over time, i.e., the interaction between the linear time variable and the groups. 
Therapy interruption 
To estimate the chances for the three outcomes regarding therapy interruption at each time of measurement, we 
calculated odds ratios for the intervention and the control group. Since almost none of the odds ratios are 
statistically different from 1, we describe mere trends. The first outcome “No UTI” is the reference category. For 
T1 and with respect to the first outcome No UTI, the intervention group has a 1.93 times higher chance to 
experience an oncologist’s advised UTI than the control group; at T2 even a 2.36 higher chance, before the trend 
decreases (T3 1.66, T4 1.53). By contrast, the chance to experience a patient-initiated UTI is lower for the 
intervention group. Across the four times of measurement, a clear trend can be noticed. The intervention group 
always has higher chances to not experience a patient-initiated UTI, especially at T1 0.14 (p = 0.01) (T2 0.71, T3 
0.33, T4 0.45) (Table 2). 
Discussion 
This cluster-randomized trial aimed to investigate the effectiveness of a standardized patient education program 
in oral cancer care provided by oncology nurses in the outpatient setting. The results elucidate that a patient 
education program can help to reduce therapy-related side effects of fatigue, nausea, pain, skin rash, and 
vomiting, and to reduce unplanned therapy interruptions without the physicians’ involvement. These effects can 
be achieved with the aid of minimal additional resources of time from the physician. These trends correspond to 
findings from other trials which integrate a patient education program provided by nurses in oncology care and 
also reported better symptom management and fewer critical events [11, 15, 23]. In contrast to most of these 
studies, we focused on the critical event “unplanned therapy interruption” instead of, e.g., hospitalization rate. 
The therapy-related side effects mainly occurred between the start of therapy and T3 (8 weeks). While the side 
effects in the intervention group remained stable during T1 and T2, the side effects in the control group increased 
until T3 (Fig. 2). Hence, the most crucial time for a supportive care intervention in oral cancer therapy seems to be 
in the first 2 months after the treatment has started, which is supported by a previous study from Molassiotes et 
al. [11]. When starting therapy, patients receive plenty of information about their treatment by their physician and 
others. Patients often cannot digest and assimilate all the information in a short time [10, 24]. An education 
program and additional support from nurses seem to be useful in oncology care for framing this situation, to meet 
patients’ needs appropriately and overcome communication limits of the patient [1, 10–14]. Through the education 
program, the patient is continuously monitored by the oncology nurse. This frequent contact with the patients 
enables oncology nurses and physicians to provide early detection and intervention concerning adverse events, 
especially in the case of new drugs with a broad spectrum of less well-known effects [3, 15, 25]. A continuous 
monitoring can protect oncology patients from therapy-related side effects, e.g., skin rash, hand-foot syndrome, 




Table 2 Therapy interruptions 








1.93 (0.52, 7.21) 
p = 0.34 
2.36 (0.49, 11.41) 
p = 0.30 
1.66 (0.50, 5.50) 
p = 0.43 
1.53 (0.43, 5.44) 




0.14 (0.03, 0.69) 
p = 0.01 
0.71 (0.15, 3.27) 
p = 0.66 
0.33 (0.07, 1.47) 
p = 0.16 
0.45 (0.12, 1.75) 
p = 0.27 
N 159 143 128 97 
Note: intervention vs. standard care group (odds ratios, 95% CI; “No unplanned therapy interruptions” = reference category) 
The close contact with the oncology nurse and the physician may have an additional benefit for the patient, 
because it has the potential to improve the patient-physician collaboration [29]. The study showed that unplanned 
therapy interruptions by recommendation of the physician occurred more often in the intervention group. Through 
continuous monitoring, the physician has the ability to adjust or interrupt the therapy if necessary and prevent 
further side effects [16, 30]. In the control group, patients decided more often to interrupt the therapy without 
informing the physician. This may indicate that the patients in the intervention group were better able to react 
adequately at times of critical events.  
Our study is limited in that it can only reveal trends. Measurable effects are small, and since we did not achieve 
the expected number of patients in both groups, namely, at least 20 patients in every attending practice and 
altogether 560 patients, the resulting evidence is restricted. There are few significant differences between the 
groups. Future studies should repeat the trial with a larger sample. Due to the fact that our trial included a large 
number of oral agents and types of cancer, the subgroups of patients were often too small to get reliable data on 
specific oral agents and cancer types. The analysis regarding side effects and unplanned therapy interruptions 
was only conducted for the two study groups and not on single oral agents or types of cancer. Therefore, we are 
only able to give a general statement on the effectiveness of a standardized patient education program.  
The findings of our trial show the great potential of a nurse-performed standardized patient education program 
in oral cancer therapy. Further studies should address the specific needs of different patient groups to improve 
proactive therapy management. This could for example be achieved by handing out a questionnaire to the 
patients which asks for important aspects from their point of view. Additionally, research should focus on more 
specifically defined disease situations (i.e., solid tumors, leukemias, etc.) and probably age subgroups. 
Furthermore, in order to make patient education programs in oncology more popular and sophisticated, their 
impact on hard clinical end points (e.g., progression-free survival and overall survival) and cost-effectiveness 
have to be evaluated. 
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